Cancer Biomarkers Market (By Type: Breast Cancer, Prostate Cancer, Colorectal Cancer, Cervical Cancer, Liver Cancer, Lung Cancer, Others; By Biomolecule: Genetic Biomarkers, Epigenetic Biomarkers, Metabolic Biomarkers, Proteomic Biomarkers, Others; By Application: Drug Discovery and Development, Diagnostics, Personalized Medicine, Others; By Profiling Technology; By End User) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2022 – 2030

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Cancer Biomarkers Market 

5.1. COVID-19 Landscape: Cancer Biomarkers Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Cancer Biomarkers Market, By Type

8.1. Cancer Biomarkers Market, by Type, 2022-2030

8.1.1. Breast Cancer

8.1.1.1. Market Revenue and Forecast (2017-2030)

8.1.2. Prostate Cancer

8.1.2.1. Market Revenue and Forecast (2017-2030)

8.1.3. Colorectal Cancer

8.1.3.1. Market Revenue and Forecast (2017-2030)

8.1.4. Cervical Cancer

8.1.4.1. Market Revenue and Forecast (2017-2030)

8.1.5. Liver Cancer

8.1.5.1. Market Revenue and Forecast (2017-2030)

8.1.6. Lung Cancer

8.1.6.1. Market Revenue and Forecast (2017-2030)

8.1.7. Others

8.1.7.1. Market Revenue and Forecast (2017-2030)

Chapter 9. Global Cancer Biomarkers Market, By Biomolecule Type

9.1. Cancer Biomarkers Market, by Biomolecule Type, 2022-2030

9.1.1. Genetic Biomarkers

9.1.1.1. Market Revenue and Forecast (2017-2030)

9.1.2. Epigenetic Biomarkers

9.1.2.1. Market Revenue and Forecast (2017-2030)

9.1.3. Metabolic Biomarkers

9.1.3.1. Market Revenue and Forecast (2017-2030)

9.1.4. Proteomic Biomarkers

9.1.4.1. Market Revenue and Forecast (2017-2030)

9.1.5. Others

9.1.5.1. Market Revenue and Forecast (2017-2030)

Chapter 10. Global Cancer Biomarkers Market, By Application Type 

10.1. Cancer Biomarkers Market, by Application Type, 2022-2030

10.1.1. Drug Discovery and Development

10.1.1.1. Market Revenue and Forecast (2017-2030)

10.1.2. Diagnostics

10.1.2.1. Market Revenue and Forecast (2017-2030)

10.1.3. Personalized Medicine

10.1.3.1. Market Revenue and Forecast (2017-2030)

10.1.4. Others

10.1.4.1. Market Revenue and Forecast (2017-2030)

Chapter 11. Global Cancer Biomarkers Market, By Profiling Technology

11.1. Cancer Biomarkers Market, by Profiling Technology Type, 2022-2030

11.1.1. Omic Technologies

11.1.1.1. Market Revenue and Forecast (2017-2030)

11.1.2. Imaging Technologies

11.1.2.1. Market Revenue and Forecast (2017-2030)

11.1.3. Immunoassays

11.1.3.1. Market Revenue and Forecast (2017-2030)

11.1.4. Cytogenetics-based Tests

11.1.4.1. Market Revenue and Forecast (2017-2030)

Chapter 12. Global Cancer Biomarkers Market, By End User Type

12.1. Cancer Biomarkers Market, by End User, 2022-2030

12.1.1. Hospitals

12.1.1.1. Market Revenue and Forecast (2017-2030)

12.1.2. Academic and Cancer Research Institutes

12.1.2.1. Market Revenue and Forecast (2017-2030)

12.1.3. Ambulatory Surgical Centres

12.1.3.1. Market Revenue and Forecast (2017-2030)

12.1.4. Diagnostic Laboratories

12.1.4.1. Market Revenue and Forecast (2017-2030)

Chapter 13. Global Cancer Biomarkers  Market, Regional Estimates and Trend Forecast

13.1. North America

13.1.1. Market Revenue and Forecast, by Type (2017-2030)

13.1.2. Market Revenue and Forecast, by Biomolecule (2017-2030)

13.1.3. Market Revenue and Forecast, by Application (2017-2030)

13.1.4. Market Revenue and Forecast, by Profiling Technology (2017-2030)

13.1.5. Market Revenue and Forecast, by End User (2017-2030)

13.1.6. U.S.

13.1.6.1. Market Revenue and Forecast, by Type (2017-2030)

13.1.6.2. Market Revenue and Forecast, by Biomolecule (2017-2030)

13.1.6.3. Market Revenue and Forecast, by Application (2017-2030)

13.1.6.4. Market Revenue and Forecast, by Profiling Technology (2017-2030)

13.1.7. Market Revenue and Forecast, by End User (2017-2030) 

13.1.8. Rest of North America

13.1.8.1. Market Revenue and Forecast, by Type (2017-2030)

13.1.8.2. Market Revenue and Forecast, by Biomolecule (2017-2030)

13.1.8.3. Market Revenue and Forecast, by Application (2017-2030)

13.1.8.4. Market Revenue and Forecast, by Profiling Technology (2017-2030)

13.1.8.5. Market Revenue and Forecast, by End User (2017-2030)

13.2. Europe

13.2.1. Market Revenue and Forecast, by Type (2017-2030)

13.2.2. Market Revenue and Forecast, by Biomolecule (2017-2030)

13.2.3. Market Revenue and Forecast, by Application (2017-2030)

13.2.4. Market Revenue and Forecast, by Profiling Technology (2017-2030) 

13.2.5. Market Revenue and Forecast, by End User (2017-2030) 

13.2.6. UK

13.2.6.1. Market Revenue and Forecast, by Type (2017-2030)

13.2.6.2. Market Revenue and Forecast, by Biomolecule (2017-2030)

13.2.6.3. Market Revenue and Forecast, by Application (2017-2030)

13.2.7. Market Revenue and Forecast, by Profiling Technology (2017-2030) 

13.2.8. Market Revenue and Forecast, by End User (2017-2030) 

13.2.9. Germany

13.2.9.1. Market Revenue and Forecast, by Type (2017-2030)

13.2.9.2. Market Revenue and Forecast, by Biomolecule (2017-2030)

13.2.9.3. Market Revenue and Forecast, by Application (2017-2030)

13.2.10. Market Revenue and Forecast, by Profiling Technology (2017-2030)

13.2.11. Market Revenue and Forecast, by End User (2017-2030)

13.2.12. France

13.2.12.1. Market Revenue and Forecast, by Type (2017-2030)

13.2.12.2. Market Revenue and Forecast, by Biomolecule (2017-2030)

13.2.12.3. Market Revenue and Forecast, by Application (2017-2030)

13.2.12.4. Market Revenue and Forecast, by Profiling Technology (2017-2030)

13.2.13. Market Revenue and Forecast, by End User (2017-2030)

13.2.14. Rest of Europe

13.2.14.1. Market Revenue and Forecast, by Type (2017-2030)

13.2.14.2. Market Revenue and Forecast, by Biomolecule (2017-2030)

13.2.14.3. Market Revenue and Forecast, by Application (2017-2030)

13.2.14.4. Market Revenue and Forecast, by Profiling Technology (2017-2030)

13.2.15. Market Revenue and Forecast, by End User (2017-2030)

13.3. APAC

13.3.1. Market Revenue and Forecast, by Type (2017-2030)

13.3.2. Market Revenue and Forecast, by Biomolecule (2017-2030)

13.3.3. Market Revenue and Forecast, by Application (2017-2030)

13.3.4. Market Revenue and Forecast, by Profiling Technology (2017-2030)

13.3.5. Market Revenue and Forecast, by End User (2017-2030)

13.3.6. India

13.3.6.1. Market Revenue and Forecast, by Type (2017-2030)

13.3.6.2. Market Revenue and Forecast, by Biomolecule (2017-2030)

13.3.6.3. Market Revenue and Forecast, by Application (2017-2030)

13.3.6.4. Market Revenue and Forecast, by Profiling Technology (2017-2030)

13.3.7. Market Revenue and Forecast, by End User (2017-2030)

13.3.8. China

13.3.8.1. Market Revenue and Forecast, by Type (2017-2030)

13.3.8.2. Market Revenue and Forecast, by Biomolecule (2017-2030)

13.3.8.3. Market Revenue and Forecast, by Application (2017-2030)

13.3.8.4. Market Revenue and Forecast, by Profiling Technology (2017-2030)

13.3.9. Market Revenue and Forecast, by End User (2017-2030)

13.3.10. Japan

13.3.10.1. Market Revenue and Forecast, by Type (2017-2030)

13.3.10.2. Market Revenue and Forecast, by Biomolecule (2017-2030)

13.3.10.3. Market Revenue and Forecast, by Application (2017-2030)

13.3.10.4. Market Revenue and Forecast, by Profiling Technology (2017-2030)

13.3.10.5. Market Revenue and Forecast, by End User (2017-2030)

13.3.11. Rest of APAC

13.3.11.1. Market Revenue and Forecast, by Type (2017-2030)

13.3.11.2. Market Revenue and Forecast, by Biomolecule (2017-2030)

13.3.11.3. Market Revenue and Forecast, by Application (2017-2030)

13.3.11.4. Market Revenue and Forecast, by Profiling Technology (2017-2030)

13.3.11.5. Market Revenue and Forecast, by End User (2017-2030)

13.4. MEA

13.4.1. Market Revenue and Forecast, by Type (2017-2030)

13.4.2. Market Revenue and Forecast, by Biomolecule (2017-2030)

13.4.3. Market Revenue and Forecast, by Application (2017-2030)

13.4.4. Market Revenue and Forecast, by Profiling Technology (2017-2030)

13.4.5. Market Revenue and Forecast, by End User (2017-2030)

13.4.6. GCC

13.4.6.1. Market Revenue and Forecast, by Type (2017-2030)

13.4.6.2. Market Revenue and Forecast, by Biomolecule (2017-2030)

13.4.6.3. Market Revenue and Forecast, by Application (2017-2030)

13.4.6.4. Market Revenue and Forecast, by Profiling Technology (2017-2030)

13.4.7. Market Revenue and Forecast, by End User (2017-2030)

13.4.8. North Africa

13.4.8.1. Market Revenue and Forecast, by Type (2017-2030)

13.4.8.2. Market Revenue and Forecast, by Biomolecule (2017-2030)

13.4.8.3. Market Revenue and Forecast, by Application (2017-2030)

13.4.8.4. Market Revenue and Forecast, by Profiling Technology (2017-2030)

13.4.9. Market Revenue and Forecast, by End User (2017-2030)

13.4.10. South Africa

13.4.10.1. Market Revenue and Forecast, by Type (2017-2030)

13.4.10.2. Market Revenue and Forecast, by Biomolecule (2017-2030)

13.4.10.3. Market Revenue and Forecast, by Application (2017-2030)

13.4.10.4. Market Revenue and Forecast, by Profiling Technology (2017-2030)

13.4.10.5. Market Revenue and Forecast, by End User (2017-2030)

13.4.11. Rest of MEA

13.4.11.1. Market Revenue and Forecast, by Type (2017-2030)

13.4.11.2. Market Revenue and Forecast, by Biomolecule (2017-2030)

13.4.11.3. Market Revenue and Forecast, by Application (2017-2030)

13.4.11.4. Market Revenue and Forecast, by Profiling Technology (2017-2030)

13.4.11.5. Market Revenue and Forecast, by End User (2017-2030)

13.5. Latin America

13.5.1. Market Revenue and Forecast, by Type (2017-2030)

13.5.2. Market Revenue and Forecast, by Biomolecule (2017-2030)

13.5.3. Market Revenue and Forecast, by Application (2017-2030)

13.5.4. Market Revenue and Forecast, by Profiling Technology (2017-2030)

13.5.5. Market Revenue and Forecast, by End User (2017-2030)

13.5.6. Brazil

13.5.6.1. Market Revenue and Forecast, by Type (2017-2030)

13.5.6.2. Market Revenue and Forecast, by Biomolecule (2017-2030)

13.5.6.3. Market Revenue and Forecast, by Application (2017-2030)

13.5.6.4. Market Revenue and Forecast, by Profiling Technology (2017-2030)

13.5.7. Market Revenue and Forecast, by End User (2017-2030)

13.5.8. Rest of LATAM

13.5.8.1. Market Revenue and Forecast, by Type (2017-2030)

13.5.8.2. Market Revenue and Forecast, by Biomolecule (2017-2030)

13.5.8.3. Market Revenue and Forecast, by Application (2017-2030)

13.5.8.4. Market Revenue and Forecast, by Profiling Technology (2017-2030)

13.5.8.5. Market Revenue and Forecast, by End User (2017-2030)

Chapter 14. Company Profiles

14.1. F. Hoffmann-La Roche Ltd.

14.1.1. Company Overview

14.1.2. Product Offerings

14.1.3. Financial Performance

14.1.4. Recent Initiatives

14.2. Thermo Fisher Scientific Inc.

14.2.1. Company Overview

14.2.2. Product Offerings

14.2.3. Financial Performance

14.2.4. Recent Initiatives

14.3. QIAGEN N.V.

14.3.1. Company Overview

14.3.2. Product Offerings

14.3.3. Financial Performance

14.3.4. Recent Initiatives

14.4. Illumina Inc.

14.4.1. Company Overview

14.4.2. Product Offerings

14.4.3. Financial Performance

14.4.4. Recent Initiatives

14.5. Bio-Rad Laboratories Inc.

14.5.1. Company Overview

14.5.2. Product Offerings

14.5.3. Financial Performance

14.5.4. Recent Initiatives

14.6. Abbott Laboratories

14.6.1. Company Overview

14.6.2. Product Offerings

14.6.3. Financial Performance

14.6.4. Recent Initiatives

14.7. Exact Sciences

14.7.1. Company Overview

14.7.2. Product Offerings

14.7.3. Financial Performance

14.7.4. Recent Initiatives

14.8. Meso Scale Diagnostics LLC

14.8.1. Company Overview

14.8.2. Product Offerings

14.8.3. Financial Performance

14.8.4. Recent Initiatives

14.9. Seegene Technologies Inc.

14.9.1. Company Overview

14.9.2. Product Offerings

14.9.3. Financial Performance

14.9.4. Recent Initiatives

14.10. Siemens Healthineers

14.10.1. Company Overview

14.10.2. Product Offerings

14.10.3. Financial Performance

14.10.4. Recent Initiatives

Chapter 15. Research Methodology

15.1. Primary Research

15.2. Secondary Research

15.3. Assumptions

Chapter 16. Appendix

16.1. About Us

16.2. Glossary of Terms

PROCEED TO BUY

   USD 4500
   USD 7000
   USD 9000

ASK FOR SAMPLE

No cookie-cutter, only authentic analysis – take the 1st step to become an Precedence Research client

Get a Sample